Grifols Valuation
Is OZTA undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
3/6Valuation Score 3/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of OZTA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: OZTA (€11) is trading below our estimate of fair value (€25.1)
Significantly Below Fair Value: OZTA is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for OZTA?
Key metric: As OZTA is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is OZTA's PE Ratio? | |
|---|---|
| PE Ratio | 45.9x |
| Earnings | €161.49m |
| Market Cap | €6.90b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 2.7x |
| Enterprise Value/EBITDA | 14.8x |
| PEG Ratio | 1.5x |
Price to Earnings Ratio vs Peers
How does OZTA's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 63.2x | ||
BIO3 Biotest | 26.9x | 82.7% | €1.4b |
FYB Formycon | 12.8x | 30.8% | €820.2m |
1SXP SCHOTT Pharma KGaA | 25.7x | 15.9% | €3.9b |
SRT3 Sartorius | 187.6x | 36.4% | €13.1b |
OZTA Grifols | 45.9x | 31.3% | €6.9b |
Price-To-Earnings vs Peers: OZTA is good value based on its Price-To-Earnings Ratio (45.9x) compared to the peer average (63.2x).
Price to Earnings Ratio vs Industry
How does OZTA's PE Ratio compare vs other companies in the European Biotechs Industry?
| 5 Companies | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
| 5 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Earnings vs Industry: OZTA is expensive based on its Price-To-Earnings Ratio (45.9x) compared to the European Biotechs industry average (26.8x).
Price to Earnings Ratio vs Fair Ratio
What is OZTA's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 45.9x |
| Fair PE Ratio | 24.9x |
Price-To-Earnings vs Fair Ratio: OZTA is expensive based on its Price-To-Earnings Ratio (45.9x) compared to the estimated Fair Price-To-Earnings Ratio (24.9x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | €11.00 | €17.10 +55.4% | 29.5% | €27.00 | €9.00 | n/a | 13 |
| Nov ’25 | €10.17 | €16.94 +66.6% | 30.7% | €27.00 | €9.00 | n/a | 13 |
| Oct ’25 | €10.17 | €17.72 +74.3% | 29.1% | €25.00 | €9.00 | n/a | 15 |
| Sep ’25 | €9.81 | €17.72 +80.7% | 29.1% | €25.00 | €9.00 | n/a | 15 |
| Aug ’25 | €9.00 | €17.52 +94.7% | 28.8% | €25.00 | €9.00 | n/a | 15 |
| Jul ’25 | €8.10 | €17.41 +114.9% | 30.0% | €25.00 | €9.00 | n/a | 16 |
| Jun ’25 | €9.26 | €17.53 +89.3% | 31.0% | €25.00 | €8.00 | n/a | 15 |
| May ’25 | €8.51 | €17.50 +105.7% | 30.2% | €25.00 | €7.00 | n/a | 14 |
| Apr ’25 | €8.24 | €18.86 +129.0% | 30.6% | €27.80 | €7.00 | n/a | 15 |
| Mar ’25 | €8.80 | €18.88 +114.6% | 27.0% | €27.80 | €9.00 | n/a | 16 |
| Feb ’25 | €10.01 | €19.08 +90.6% | 26.3% | €27.80 | €9.00 | n/a | 16 |
| Jan ’25 | €15.02 | €18.73 +24.7% | 21.3% | €24.80 | €12.00 | n/a | 18 |
| Dec ’24 | €12.87 | €18.48 +43.6% | 23.8% | €24.80 | €11.00 | n/a | 17 |
| Nov ’24 | €10.53 | €18.36 +74.5% | 24.2% | €24.90 | €11.50 | €10.17 | 17 |
| Oct ’24 | €12.08 | €18.52 +53.4% | 23.6% | €25.00 | €11.50 | €10.17 | 17 |
| Sep ’24 | €12.56 | €18.08 +44.0% | 25.3% | €25.00 | €11.50 | €9.81 | 17 |
| Aug ’24 | €13.52 | €17.81 +31.8% | 27.7% | €25.00 | €10.00 | €9.00 | 17 |
| Jul ’24 | €11.44 | €17.66 +54.4% | 28.5% | €24.90 | €10.00 | €8.10 | 17 |
| Jun ’24 | €10.83 | €17.53 +61.9% | 28.3% | €24.90 | €10.00 | €9.26 | 17 |
| May ’24 | €9.28 | €17.70 +90.7% | 32.3% | €30.00 | €10.00 | €8.51 | 17 |
| Apr ’24 | €9.09 | €18.04 +98.6% | 31.5% | €30.00 | €10.00 | €8.24 | 17 |
| Mar ’24 | €11.66 | €18.16 +55.8% | 31.0% | €30.00 | €10.00 | €8.80 | 17 |
| Feb ’24 | €12.04 | €17.53 +45.6% | 36.9% | €30.00 | €9.00 | €10.01 | 17 |
| Jan ’24 | €10.85 | €17.19 +58.4% | 38.7% | €30.00 | €9.00 | €15.02 | 17 |
| Dec ’23 | €10.30 | €17.76 +72.4% | 38.4% | €30.00 | €9.00 | €12.87 | 17 |
| Nov ’23 | €9.01 | €19.88 +120.6% | 34.0% | €30.00 | €8.00 | €10.53 | 16 |
Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.
Discover undervalued companies
Perrigo
US$3.7b
Provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally.
PIG
US$25.29
7D
3.1%
1Y
-7.7%
Amneal Pharmaceuticals
US$2.6b
Develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide.
2DT
US$7.60
7D
-2.6%
1Y
86.3%
Almirall
€1.8b
A biopharmaceutical company, engages in the purchase, manufacture, storage, and sale of skin-health medicines in Europe, the Middle East, the United States, Asia, and Africa.
E2Z
€8.35
7D
-4.5%
1Y
-2.3%